Catalog No.S3021

Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.

Price Stock Quantity  
USD 120 In stock
USD 90 In stock
USD 170 In stock
USD 270 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Rimonabant Chemical Structure

Rimonabant Chemical Structure
Molecular Weight: 463.79

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Rimonabant is available in the following compound libraries:

Product Information

  • Compare Cannabinoid Receptor Chemicals
    Compare Cannabinoid Receptor Products
  • Research Area

Product Description

Biological Activity

Description Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.
Targets hCB1 [1] hCB2 [1] ACAT [2]
IC50 13.6 nM 1.64 μM 1.5 μM-2.9 μM
In vitro Rimonabant dose-dependently reduces ACAT activity in Raw264.7macrophages with IC50 of 2.9 μM and isolated peritoneal macrophages. Rimonabant inhibits ACATactivity in intact CHO-ACAT1 and CHO-ACAT2 cells and in cell-free assays with approximately equal efficiency with IC50 of 1.5 μM and 2.2 μM for CHO-ACAT1 and CHO-ACAT2, respectively. Consistent with ACAT inhibition, Rimonabant treatment blocks ACAT dependent processes in macrophages, oxysterol-induced apoptosis and acetylated-LDL induced foam cell formation. [2] Rimonabant antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes in a concentration-dependent manner. [3] Rimonabant significantly reduces cell growth and induces cell death of human colorectal cancer cells (DLD-1, CaCo-2 and SW620). Rimonabant is able to alter cell cycle distribution in all the cell lines tested. Particularly, Rimonabant produces a G2/M cell cycle arrest in DLD-1 cells without inducing apoptosis or necrosis. [4]
In vivo Rimonabant is administered intraperitoneally or orally potently and dose-dependently antagonize classical pharmacological and behavioural effectos of cannabinoid receptor agonists. [3] In the mouse model of azoxymethane-induced colon carcinogenesis, Rimonabant significantly decreased aberrant crypt foci (ACF) formation, which precedes colorectal cancer. [4] Rimonabant (10 mg/kg by gavage) is fed for 2 weeks to 3-month-old male obese Zucker rats as an impaired glucose tolerance model and for 10 weeks to 6-month-old male obese Zucker rats as a model of the metabolic syndrome. RANTES (Regulated upon Activation, Normal T cell Expressed, and Secreted) and MCP-1 (monocyte chemotactic protein-1) serum levels are increased in obese vs lean Zucker rats and significantly reduced by long-term treatment with Rimonabant, which slowes weight gain in rats with the metabolic syndrome. Neutrophils and monocytes are significantly increased in young and old obese vs lean Zucker rats and lowered by Rimonabant. Platelet-bound fibrinogen is significantly enhanced in obese vs lean Zucker rats of both age, and is reduced by Rimonabant. Platelets from obese rats are more sensitive to thrombin-induced aggregation and adhesion to fibrinogen, which are both attenuated by Rimonabant therapy. [5]
Features Efficacious to induce weight reduction and improvements in cardiometabolic risk factors, however was withdrawn in 2009 due to severe depressive disorder and anxiety.

Protocol(Only for Reference)

Kinase Assay: [1]

Radioligand Binding Assay Human CB1 and CB2 stably transfect HEK 293 cells and cell membrane is purified. 0.2-8 μg of the purified membrane is incubated with 0.75 nM [3H] CP55,940 and Rimonabant in the incubation buffer (50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, 0.3%BSA, pH 7.4). The non-specific binding is defined in the presence of 1 μM of CP55,940. The reactions are incubated for one and a half hours at 30 °C in Multiscreen. The reactions are terminated by manifold filtration and washed four times with ice-cold wash buffer (50mM Tris, pH 7.4, 0.25% BSA).The radioactivity bound to the filters is measured by Topcount. The IC50 is determined as the concentration of Rimonabant required to inhibit 50% of the binding of [3H] CP55,940 and calculated by non-linear regression.
Eu-GTP Binding Assay The Eu-GTP binding assay is performed using the DELFIA Eu-GTP binding kit, with minor modications as described in the following: 1–4 μg of puried membrane is incubated with the compound of interest and 20 nM CP55,940 in the assay buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 100 μg/mL saponin, 5 mM MgCl2, 2 μg GDP, 0.5% BSA) at 30 ℃ for 60 minutes in acroplates. Following the addition of Eu-GTP and incubation for 30 minutes at 30 ℃, the assay is terminated by washing four times with the washing buffer provided in the kit. The fluorescence signal of the Eu-GTP is determined with a Victor 2 multilabel reader. The EC50 of the tested compounds at inhibiting 50% of the CP55,940-stimulated Eu-GTP binding is determined from the dose–response curves using non-linear regression.

Cell Assay: [2]

Cell lines Raw 264.7 cells
Concentrations 0,1,4 μM
Incubation Time 17 hours
Method Raw 264.7 cells (2 × 106 /well) in 12-well plates are rinsed with PBS and refed culture media supplemented with varying amounts of Rimonabant 1 hour prior to supplementation with 7-ketocholesterol (7KC). All wells are adjusted to receive equal amounts of vehicle. Following 16-hour incubation, caspase-3 and caspase 3-like activity are determined using a fluorogenic substrate (Ac-DEVD-AFC) and a spectrofluorometer equipped with a microplate reader.

Animal Study: [3]

Animal Models Male mice and male rats
Formulation Rimonabant is dissolved in two drops of Tween 80, diluted in distilled water.
Dosages 20 ml/kg (mice) and 5 ml/kg (rats)
Administration Rimonabant is administered i.p. (30 minutes) or p.o. (1hour) before the i.v. injection of WIN55212-2.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Chu CM, et al, Org Biomol Chem, 2008, 6(18), 3399-3407

[2] Netherland C, et al, Biochem Biophys Res Commun, 2010, 398(4), 671-676.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT00754689 Withdrawn Diabetes Mellitus, Type 2 Sanofi September 2008 Phase 3
NCT00750347 Completed Pain University Hospital, Clermont-Ferrand September 2008 Phase 1
NCT00690456 Terminated Diabetes Mellitus, Type 2 Sanofi May 2008 Phase 3
NCT00678483 Terminated Obesity|Weight Loss Sanofi April 2008 Phase 3
NCT00656487 Completed Cannabis Dependence|Cannabis Withdrawal The Scripps Research Institute|National Institute on Drug  ...more The Scripps Research Institute|National Institute on Drug Abuse (NIDA) April 2008 --

view more

Chemical Information

Download Rimonabant SDF
Molecular Weight (MW) 463.79


CAS No. 168273-06-1
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms SR141716
Solubility (25°C) * In vitro DMSO 25 mg/mL (53.9 mM)
Ethanol 2 mg/mL (4.31 mM)
Water <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Cannabinoid Receptor Products

  • SB225002

    SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.

  • Smoothened Agonist (SAG) HCl

    Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.

  • SB-334867

    SB-334867 is a selective orexin-1 (OX1) receptor antagonist.

  • Org 27569

    Org 27569 is an allosteric modulator of cannabinoid CB1 receptor, induces a CB1 receptor state that is characterized by enhanced agonist affinity and decreased inverse agonist affinity.

    Features:Traps the receptor in a distinct agonist-bound, but non-signaling conformational state.

  • AM1241

    AM-1241 is a selective cannabinoid CB2 receptor agonist with Ki of 3.4 nM, exhibits 82-fold selectivity over CB1 receptor.

  • GW842166X

    GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2.

    Features:Possesses selective affinity for CB2 than CB1.

  • BML-190

    BML-190 is a selective cannabinoid CB2 receptor inverse agonist with Ki of 435 nM, with 50-fold selectivity over CB1 receptor.

  • AM251

    AM251 block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 receptors in brain.

    Features:A selective cannabinoid 1 blocker.

  • Otenabant (CP-945598) HCl

    Otenabant (CP-945598) HCl is a potent and selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor. Phase 1.

  • Vismodegib (GDC-0449)

    Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

Recently Viewed Items

Tags: buy Rimonabant | Rimonabant ic50 | Rimonabant price | Rimonabant cost | Rimonabant solubility dmso | Rimonabant purchase | Rimonabant manufacturer | Rimonabant research buy | Rimonabant order | Rimonabant mouse | Rimonabant chemical structure | Rimonabant mw | Rimonabant molecular weight | Rimonabant datasheet | Rimonabant supplier | Rimonabant in vitro | Rimonabant cell line | Rimonabant concentration | Rimonabant nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us